Inactive Instrument

Analyst Reco. Provention Bio, Inc.

Equities

PRVB

US74374N1028

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

HC Wainwright Downgrades Provention Bio to Neutral From Buy, Adjusts Price Target to $25 From $16	23-03-15	MT
SMBC Nikko Downgrades Provention Bio to Neutral From Outperform, Raises Price Target to $25 From $15	23-03-14	MT
Jefferies Downgrades Provention Bio to Hold From Buy, Price Target is $25	23-03-14	MT
Chardan Adjusts Provention Bio Price Target to $25 From $30, Maintains Buy Rating	23-03-13	MT
HC Wainwright Trims Price Target on Provention Bio to $16 From $18, Maintains Buy Rating	23-02-15	MT
Jefferies Adjusts Price Target on Provention Bio to $22 From $18, Maintains Buy Rating	22-11-21	MT
SVB Securities Adjusts Provention Bio's Price Target to $19 From $16, Keeps Outperform Rating	22-11-21	MT
Chardan Lifts Price Target on Provention Bio to $30 From $24, Keeps Buy Rating	22-11-21	MT
Jefferies Adjusts Price Target on Provention Bio to $22 From $18, Maintains Buy Rating	22-11-18	MT
Oppenheimer Adjusts Provention Bio Price Target to $18 From $14, Maintains Outperform Rating	22-11-18	MT
RBC Lifts Provention Bio's Price Target to $9 From $8, Keeps Sector Perform, Speculative Risk Rating	22-11-04	MT
Chardan Increases Price Target on Provention Bio to $24 From $21, Affirms Buy Rating	22-11-04	MT
Jefferies Adjusts Provention Bio's Price Target to $15 From $10, Reiterates Buy Rating	22-10-07	MT
Jefferies Initiates Provention Bio at Buy With $10 Price Target	22-09-20	MT
Oppenheimer Adjusts Provention Bio Price Target to $14 From $16, Maintains Outperform Rating	22-08-08	MT
Chardan Research Lowers Provention Bio's Price Target to $21 From $22.50, Maintains Buy Rating	22-08-05	MT
Chardan Research Trims Price Target on Provention Bio to $21 From $22.50, Reiterates Buy Rating	22-08-05	MT
HC Wainwright Adjusts Provention Bio's Price Target to $18 From $25, Reiterates Buy Rating	22-07-11	MT
SMBC Nikko Upgrades Provention Bio to Outperform From Neutral, Raises Price Target to $15 From $8	21-11-23	MT
PROVENTION BIO : Oppenheimer Adjusts Provention Bio PT to $16 From $18, Maintains Outperform Rating	21-08-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Provention Bio, Inc.

Equities

PRVB

US74374N1028

Analyst Reco.

Filters